Genetic Testing (PGT/PGD)

Genetic Testing Before Embryo Transfer: Clarity When Every Decision Feels Important

For many people pursuing IVF, the question is not simply whether pregnancy is possible. It is whether there is a way to reduce the chance of passing on a known genetic condition, lower the likelihood of miscarriage related to chromosome differences, or make more informed choices before an embryo is transferred. These concerns can carry years of family history, previous loss, unsuccessful treatment, or difficult medical decisions.

Preimplantation genetic testing, often called PGT or historically PGD, offers a way to examine embryos created through IVF before pregnancy begins. Depending on the reason for testing, it can look for a specific inherited gene change, assess chromosome number, or evaluate structural chromosome rearrangements that may affect embryo development. The purpose is not to create a “perfect” embryo or to predict every aspect of a child’s future health. It is to provide clinically meaningful information that helps a reproductive medicine team and prospective parents decide which embryos may be appropriate to consider for transfer.

The decision to use PGT can feel emotionally and ethically complex. Patients may worry about what the results will show, whether enough embryos will be available, how accurate testing is, whether the IVF process will be physically demanding, and whether testing is truly necessary in their circumstances. A careful consultation can make those questions more manageable. At Acibadem, reproductive endocrinologists, embryologists, genetic counselors, and, when needed, other specialists review each case in the context of the patient’s medical history, family history, fertility assessment, and personal priorities.

For some families, PGT is used to avoid transmission of a serious single-gene condition. For others, it is considered after recurrent pregnancy loss, repeated IVF failure, advanced maternal age, or a chromosome finding in one partner. The appropriate pathway is individual. A well-planned evaluation can clarify what PGT can reasonably offer, where its limitations lie, and whether another approach may be more suitable.

What Is Preimplantation Genetic Testing (PGT/PGD)?

Preimplantation genetic testing is a laboratory-based evaluation performed on a small number of cells removed from an embryo created through in vitro fertilization. The testing takes place before an embryo is transferred to the uterus. In most modern IVF programs, embryos are cultured to the blastocyst stage, usually around five to seven days after fertilization, when a few cells can be biopsied from the outer layer of the embryo. This outer layer is intended to form the placenta; the inner cell mass, which develops into the fetus, is not biopsied.

The sampled cells are analyzed in a specialized genetics laboratory. The embryo is usually frozen while results are being processed, allowing transfer to take place later in a carefully prepared frozen embryo transfer cycle. This approach gives the laboratory and clinical team time to review the results thoroughly and discuss the findings with the patient.

PGT is an umbrella term that includes several distinct forms of testing:

• PGT-M, previously often described as PGD, is used when there is a known or suspected risk of a specific monogenic, or single-gene, condition. Examples may include cystic fibrosis, thalassemia, spinal muscular atrophy, Huntington disease, fragile X syndrome, or many other inherited disorders. Before an IVF cycle, the laboratory develops a test strategy tailored to the family’s known genetic finding.
• PGT-A assesses whether an embryo has the expected number of chromosomes. Embryos with an extra or missing chromosome are described as aneuploid. Such chromosome differences are a common reason embryos do not implant, miscarry, or result in certain chromosome conditions. PGT-A may help prioritize embryos for transfer in selected patients, but it does not change an embryo’s genetic makeup or create additional embryos.
• PGT-SR is used when one prospective parent carries a structural chromosome rearrangement, such as a balanced translocation or inversion. Although a carrier may be healthy, some embryos may inherit an unbalanced chromosome arrangement that can affect implantation, miscarriage risk, or fetal development.

PGT provides information about the cells tested, but it is not identical to diagnostic genetic testing during pregnancy. A small possibility of technical limitation, mosaic findings, or discordance between sampled cells and other embryonic cells remains. For this reason, patients who become pregnant after PGT are usually advised to discuss confirmatory prenatal testing options, such as chorionic villus sampling or amniocentesis, with their obstetrician and genetic counselor.

Who May Need PGT and How Is the Need Identified?

Unlike many medical treatments, PGT is not usually prompted by physical symptoms. A person can be healthy, have regular menstrual cycles, and still carry a genetic variant or chromosome rearrangement that has implications for their embryos. The need for testing is most often identified through family history, prior reproductive history, genetic carrier screening, chromosome analysis, or testing performed after an affected pregnancy or child.

Patients may consider PGT when they have experienced recurrent miscarriage, particularly when chromosome abnormalities have been identified in pregnancy tissue or when one partner is known to carry a chromosome rearrangement. It may also be discussed after repeated unsuccessful embryo transfers, although implantation failure can have several causes and PGT is not the right answer for every patient.

For prospective parents with a known inherited condition in the family, genetic counseling is a central part of assessment. The counselor may review medical records, prior molecular test results, family pedigrees, and the inheritance pattern of the condition. If the relevant genetic change has not yet been identified, testing may be needed before PGT-M can be designed. In some cases, genetic samples from relatives are helpful to establish a reliable family-specific testing approach.

A fertility evaluation is also necessary because PGT requires IVF. This may include ovarian reserve testing, ultrasound assessment, semen analysis, infectious disease screening, and review of previous fertility treatment. The team considers age, expected egg yield, sperm factors, uterine health, prior embryo development, and the time available for treatment. These details help patients understand how likely it is that an IVF cycle will produce embryos available for testing and transfer.

Conditions and Reproductive Situations PGT Can Address

PGT-M may be considered for a broad range of inherited conditions where the familial genetic change is known and a reliable testing method can be developed. These include autosomal recessive disorders, where both partners may be carriers; autosomal dominant disorders, where one affected parent may have a chance of passing on the gene variant; and X-linked disorders, which may affect male and female children differently depending on the condition.

Examples include hemoglobin disorders such as beta-thalassemia and sickle cell disease, cystic fibrosis, spinal muscular atrophy, certain metabolic disorders, muscular dystrophies, inherited neurological conditions, and hereditary cancer predisposition syndromes in carefully evaluated circumstances. Whether PGT is appropriate depends on the specific gene, the family’s genetic result, the reliability of the assay, applicable medical and ethical considerations, and the patient’s wishes.

PGT-SR can be valuable for individuals with balanced reciprocal translocations, Robertsonian translocations, inversions, or other structural chromosome findings. A person with a balanced rearrangement often has no health concerns themselves because the overall amount of genetic material is balanced. However, embryos may receive an unbalanced amount of genetic material, which can lead to failed implantation, miscarriage, or an affected pregnancy.

PGT-A is most commonly considered in situations where the likelihood of aneuploid embryos may be higher, including increasing maternal age or certain histories of pregnancy loss. It may also be discussed with patients who have several embryos available and wish to use chromosome information to guide transfer order. Its value varies by individual circumstance. It should be considered a tool for embryo selection, not a universal requirement for IVF or a substitute for comprehensive fertility care.

PGT does not test for every genetic condition, developmental difference, birth defect, or future health concern. It cannot fully assess intelligence, personality, appearance, or all complex diseases influenced by multiple genes and environmental factors. An experienced genetic counseling discussion is essential to establish exactly what a proposed test can and cannot identify.

How PGT Is Performed: From Preparation to Embryo Transfer

The PGT process begins well before egg collection. Patients first meet with a reproductive medicine specialist to review their fertility history, genetic history, and treatment goals. If PGT-M or PGT-SR is being considered, a genetics consultation and laboratory review are particularly important. The laboratory confirms whether a validated testing strategy can be established and what samples or prior results are needed. Developing a family-specific PGT-M assay may take additional time, so planning before an IVF cycle is often beneficial.

1. Genetic and fertility assessment

Before treatment starts, the team reviews relevant genetic reports and may recommend carrier screening, confirmatory molecular testing, chromosome analysis, or further evaluation of a known family condition. Fertility tests help guide medication selection and estimate the expected response to ovarian stimulation. The discussion should also cover the possibility that no embryos, no testable embryos, or no embryos suitable for transfer may result from a cycle. Although difficult to consider, understanding these possibilities beforehand supports informed decisions.

2. Ovarian stimulation and monitoring

During an IVF cycle, fertility medications stimulate the ovaries to mature multiple eggs. Patients are monitored with ultrasound examinations and blood tests so the care team can adjust medication dosing and determine the optimal time for egg retrieval. The exact medication plan varies according to ovarian reserve, age, medical history, body response, and prior IVF outcomes.

3. Egg retrieval and fertilization

Egg retrieval is generally performed under sedation or anesthesia. Using ultrasound guidance, the physician collects eggs from the ovaries through the vagina. The procedure itself is typically brief, and most patients go home the same day with instructions for recovery.

Retrieved eggs are fertilized in the embryology laboratory. Intracytoplasmic sperm injection, or ICSI, is frequently used in PGT cycles because it supports controlled fertilization and reduces the possibility of DNA from sperm cells surrounding the egg affecting the sample. The resulting embryos are cultured in carefully controlled incubator conditions and observed as they develop.

4. Blastocyst culture and embryo biopsy

Embryos that develop to the blastocyst stage may be suitable for biopsy. Embryologists use high-resolution microscopy and micromanipulation techniques to remove a small number of trophectoderm cells. The biopsy is performed with methods designed to preserve embryo viability. Not every fertilized egg develops into a blastocyst, and not every blastocyst will be suitable for biopsy; this natural attrition is an important part of IVF counseling.

The biopsied cells are placed in secure, individually identified samples and sent for genetic analysis. Embryos are vitrified, a rapid freezing process used to preserve them until results are available. Advanced laboratory monitoring, controlled culture environments, digital witnessing systems, and precise cryopreservation methods can support accuracy, traceability, and consistent handling throughout the IVF laboratory pathway.

5. Genetic analysis and result review

Genetic testing methods may use next-generation sequencing, targeted DNA analysis, chromosome copy-number assessment, or other validated laboratory approaches depending on the type of PGT required. Results may identify embryos as suitable for consideration based on the stated testing objective, affected by a tested condition, carrying a familial variant, aneuploid, or inconclusive. In PGT-A, some results may indicate mosaicism, meaning the sampled cells show a mixture of chromosome patterns. Mosaic results require especially careful interpretation because their reproductive potential can vary.

The reproductive medicine physician and genetic counselor discuss the results in context. They explain the number and category of embryos available, what the findings mean, whether retesting may be considered in limited circumstances, and how transfer priorities are determined. Decisions should reflect clinical evidence, laboratory guidance, and the patient’s preferences.

6. Frozen embryo transfer

When a patient is ready for transfer, the uterine lining is prepared in either a natural or medication-supported cycle. Ultrasound and, when appropriate, hormonal monitoring help determine timing. The embryo transfer is usually a short outpatient procedure that does not require anesthesia. A soft catheter is passed through the cervix under ultrasound guidance, and one embryo is placed into the uterus. A pregnancy blood test is generally performed about one to two weeks later, according to the clinic’s protocol.

From initial assessment through embryo transfer, the overall timeline may range from several weeks to a few months. PGT-M preparation can extend this timeframe, especially when a custom test must be developed. The active egg retrieval portion is relatively short, but thoughtful planning and result interpretation are integral to the process.

Why Timely Evaluation Can Matter

There is rarely a need to make an immediate decision without reflection, but early evaluation can be valuable. Female age remains one of the strongest influences on egg and embryo chromosome status. As ovarian reserve and egg quality change over time, the number of embryos available for testing may decrease. For patients who know they carry a genetic condition or structural chromosome rearrangement, seeking counseling before trying to conceive or early in fertility planning can preserve more options.

Delay may also mean repeated pregnancies affected by a known genetic condition, recurrent losses, or additional cycles undertaken without a clear genetic strategy. Recurrent miscarriage can be physically and emotionally exhausting, and repeated unsuccessful transfers can add financial and psychological strain. PGT cannot prevent all loss or infertility, but identifying an underlying genetic factor may help make future care more targeted.

For hereditary conditions with later-onset symptoms, patients may feel well and may not have viewed reproductive planning as urgent. A genetic counseling appointment can provide time to understand inheritance, discuss reproductive choices, and consider whether IVF with PGT aligns with personal values. The goal is informed choice rather than pressure.

Potential Benefits of PGT

The value of PGT depends on the indication, the number and quality of embryos available, and the patient’s broader fertility profile. The following benefits describe what PGT may offer when it is clinically appropriate.

Benefit	What It Means for You
More informed embryo selection	Testing can provide genetic or chromosome information that helps the care team identify embryos to consider for transfer according to the agreed clinical objective.
Reduced likelihood of transmitting a known familial condition	For many single-gene conditions, PGT-M may help identify embryos not expected to be affected by the specific genetic change being tested.
Guidance after recurrent loss or chromosome findings	For selected patients, PGT-A or PGT-SR may clarify embryo chromosome status and support a more individualized transfer strategy.
Potentially fewer transfers to reach a viable pregnancy	When suitable embryos are available, genetic information may help prioritize transfer order. It cannot eliminate the possibility of implantation failure or miscarriage.
Time for deliberate decision-making	Because embryos are typically frozen after biopsy, patients can review results with their physician and genetic counselor before proceeding with transfer.
Reproductive planning for families with inherited risk	PGT can be one option among several, allowing families to consider pregnancy using their own eggs and sperm while addressing a known genetic concern.

Recovery Timeline After IVF and PGT

Physical recovery is mainly related to ovarian stimulation and egg retrieval; embryo biopsy occurs in the laboratory and is not felt by the patient. Emotional recovery and the waiting period for results can be equally significant.

Time Period	What Patients Can Expect
Day 1 after egg retrieval	Mild cramping, pelvic pressure, bloating, light spotting, and tiredness are common. Most patients rest at home and avoid driving after sedation.
First week	Discomfort usually improves over several days. The laboratory continues embryo culture, biopsy where appropriate, and freezing. Patients should report severe pain, heavy bleeding, shortness of breath, rapid weight gain, or worsening abdominal swelling.
One to three weeks	Genetic results may become available, depending on the test type and laboratory pathway. A consultation is arranged to review findings and discuss next steps.
First month	Many patients begin preparation for a frozen embryo transfer or plan a subsequent IVF cycle if needed. The timing depends on physical recovery, uterine preparation, results, and personal readiness.
Longer term	After pregnancy is established, routine obstetric care continues. Prenatal screening and diagnostic testing options should be reviewed because PGT does not replace prenatal assessment.

What Influences the Chances of a Good Outcome?

PGT is one element of a larger reproductive treatment plan. Its usefulness is influenced by the reason for testing and by factors that affect IVF more broadly. Maternal age, ovarian reserve, sperm quality, egg quality, embryo development, uterine health, and the number of embryos available all matter. A technically accurate test cannot compensate for embryos that do not develop to the blastocyst stage, and a result indicating an embryo is suitable for transfer cannot predict pregnancy with certainty.

For PGT-M, the clarity of the family’s genetic diagnosis and the quality of test development are central. The laboratory must be able to distinguish the relevant familial variant reliably and account for technical considerations such as allele dropout, where a gene copy may not be detected in a very small sample. For PGT-SR, the nature of the rearrangement and the laboratory’s ability to characterize chromosome segments affect interpretation. For PGT-A, the number of embryos tested, maternal age, and the possibility of mosaic results are important considerations.

Embryology laboratory quality also has a meaningful role. Consistent culture conditions, skilled biopsy technique, rigorous sample identification, validated genetic workflows, and transparent reporting support reliable care. Equally important is the clinical judgment used after results return. A specialist should interpret each report alongside embryo morphology, reproductive history, and current evidence rather than treating a laboratory category as the only factor in a decision.

Patients can support treatment by attending monitoring visits, taking medications as directed, sharing complete medical information, avoiding smoking and recreational drugs, and discussing supplements or chronic medications with the care team. However, it is important not to place undue responsibility on patients. Many factors affecting embryo development are biological and outside an individual’s control.

PGT Care for International Patients at Acibadem

International patients seeking PGT often need more than an IVF appointment. They need a plan that coordinates genetic evaluation, laboratory preparation, travel timing, treatment monitoring, and follow-up in a way that is medically appropriate and practical. Acibadem’s reproductive medicine teams work within structured diagnostic pathways that bring together fertility specialists, clinical embryologists, genetic counselors, medical geneticists, and other physicians when a patient’s health history calls for broader input.

Complex cases may be reviewed through multidisciplinary specialist discussions, particularly when there is a rare inherited condition, a chromosome rearrangement, recurrent pregnancy loss, cancer-related genetic risk, or coexisting medical concerns. This collaborative approach helps ensure that the proposed test addresses the correct genetic question and that the IVF plan reflects the patient’s overall health and reproductive goals.

Acibadem hospitals include JCI-accredited facilities, with established quality and patient safety processes relevant to international care. In reproductive medicine, modern laboratory systems, controlled embryo culture, cryopreservation, micromanipulation, and validated genetic testing pathways are used to support careful handling of embryos and dependable communication of results. Specific testing methods are selected according to the indication rather than applied as a standard package.

For patients traveling from the United States and other countries, Acibadem International patient services can help coordinate medical documentation, appointments, language support, local arrangements, and communication before and after travel. Care teams can review available records in advance so that time in Turkey is used efficiently. Some initial consultations and result discussions may be possible remotely when clinically appropriate, while key treatment steps are scheduled around the requirements of the IVF cycle.

A personalized plan also recognizes that patients differ in how much information they want, what timelines are realistic, and how they weigh genetic findings. The team’s role is to explain options clearly, discuss limitations honestly, and support decisions that are medically sound and personally meaningful.

Taking the Next Step With Informed Support

Choosing PGT is a significant decision, often made at a deeply personal point in life. Whether you are concerned about a known genetic condition, have experienced pregnancy loss, have received an unexpected chromosome result, or are exploring IVF options, a specialist review can help clarify the path ahead.

A consultation or second opinion can assess whether PGT-M, PGT-A, or PGT-SR may be relevant to your circumstances, what preparation is required, and what alternatives should also be considered. Bringing prior genetic reports, fertility records, pregnancy history, and family medical information can make the conversation more productive. Thoughtful planning cannot remove every uncertainty, but it can replace assumptions with a clearer understanding of your options.

This information is general in nature and is not a substitute for professional medical advice, genetic counseling, fertility assessment, diagnosis, or treatment recommendations from a qualified healthcare professional.